Welcome to CIDeRplus

Field	Query

	Field	Term

General Information:

Id:	4,033
Diseases:	Diabetes mellitus, type II - [OMIM] Insulin resistance Parkinson disease
Organism:	Homo sapiens
Publication type:	article
Reference:	Gieger C et al.(2008) Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum PLoS Genet. 4 [PMID: 19043545]

Interaction Information:

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41558	SNP FADS1 rs174548 decreases_activity of gene/protein FADS1 the effective allele is the minor allele
Drugbank entries	Show/Hide entries for FADS1
Drugbank DB00132	Alpha-Linolenic Acid ligand FADS1
Drugbank DB00159	Icosapent agonist FADS1
Drugbank DB00132	Alpha-Linolenic Acid ligand FADS1

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41559	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C36:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41560	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC a C20:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41561	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C38:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41562	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC ae C36:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41563	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound SM C22:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41564	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC ae C38:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41565	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC ae C38:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41566	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C38:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41567	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC ae C36:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41568	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PE a C10:0 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41569	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound SM (COOH) C18:3 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41570	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C34:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41571	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C36:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41572	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C40:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41573	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound Arachidonic acid in blood serum; the effective allele is the minor allele
Drugbank entries	Show/Hide entries for
Drugbank DB04557	Arachidonic Acid not specified PTGS1
Drugbank DB04557	Arachidonic Acid not specified ""
Drugbank DB04557	Arachidonic Acid not specified ""
Drugbank DB04557	Arachidonic Acid not specified PTGS1

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41574	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC ae C40:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41575	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C40:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41576	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound SM (OH) C26:1 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41577	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound SM C24:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41578	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PI aa C38:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41579	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound SM (OH) C24:0 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41580	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PA aa C20:7 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41581	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC ae C38:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41583	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound PC aa C38:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41584	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound Glytarylcarnitine in blood serum; the effective allele is the minor allele

Comment	SNP rs174548, one of several SNPs that lie in a linkage disequilibrium block containing the FADS1 gene was strongly associated with a number of glycerophospholipid concentrations. The FADS1 gene codes for the fatty acid delta-5 desaturase, a key enzyme in the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. The minor allele variant of this SNP results in a reduced efficiency of the fatty acid delta-5 desaturase reaction, a fact that can be inferred from the following observations: the concentrations of numerous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4, PC aa C40:5), plasmalogen/plasmenogen phosphatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4 with four and more double bonds in their polyunsaturated fatty acid (PUFA) side chains are lowest in individuals that carry the minor allele of rs174548. In particular, the concentrations of the direct product of FADS1, arachidonic acid as well as those of its lyso-phosphatidylcholine derivative (PC a C20:4) are found to be significantly reduced with increasing copy number of the minor allele.
Formal Description Interaction-ID: 41585	SNP FADS1 rs174548 decreases_quantity of drug/chemical compound SM C28:4 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41586	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PE aa C34:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41588	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PE e (COOH) C16:3 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41589	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PC aa C34:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41590	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PC ae C36:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41591	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PI aa C36:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41592	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PC aa (OH, COOH) C30:4 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41593	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PC ae C34:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41594	SNP FADS1 rs174548 increases_quantity of drug/chemical compound Lysine in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41595	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PE aa C36:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41596	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PC aa (COOH) C30:3 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41597	SNP FADS1 rs174548 increases_quantity of drug/chemical compound SM (OH,COOH) C6:0 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41598	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PI a (OH, COOH) C18:2 in blood serum; the effective allele is the minor allele

Comment	Concentrations of glycerophospholipids with three and less double bonds in their PUFA side chains show a positive association with the FADS1 genotype. These metabolites include the phosphatidylcholines PC aa C34:2 and PC aa C36:2, the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2 and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2 and PE aa C36:2, and the phosphatidylinositol PI aa C36:2.
Formal Description Interaction-ID: 41599	SNP FADS1 rs174548 increases_quantity of drug/chemical compound PC aa C36:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41611	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C38:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41614	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C40:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41615	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C38:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41616	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C36:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41617	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC aa (COOH) C30:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41618	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C38:4 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41619	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C34:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41620	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC aa (COOH) C30:3 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41621	SNP LIPC rs4775041 increases_quantity of drug/chemical compound SM C16:0 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41622	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC ae C34:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41623	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C40:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41624	SNP LIPC rs4775041 decreases_quantity of drug/chemical compound Tryptophan in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41625	SNP LIPC rs4775041 increases_quantity of drug/chemical compound SM C16:1 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41626	SNP LIPC rs4775041 increases_quantity of drug/chemical compound SM C28:3 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41627	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC aa C38:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41628	SNP LIPC rs4775041 increases_quantity of drug/chemical compound SM (COOH) C16:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41629	SNP LIPC rs4775041 increases_quantity of drug/chemical compound SM C14:0 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41630	SNP LIPC rs4775041 decreases_quantity of drug/chemical compound Leucine/Isoleucine in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41631	SNP LIPC rs4775041 increases_quantity of drug/chemical compound SM (OH, COOH) C14:1 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41632	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC ae C40:5 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41633	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PI a (OH) C12:3 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41635	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE aa C36:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41636	SNP LIPC rs4775041 decreases_quantity of drug/chemical compound Valine in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41637	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC aa (COOH) C30:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41638	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC ae C38:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41639	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC ae (OH, COOH) C30:3 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41640	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC aa C40:6 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41641	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PI aa C38:3 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41642	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE a (OH, COOH) C12:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41643	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PE e (OH) C18:1 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41644	SNP LIPC rs4775041 increases_quantity of drug/chemical compound PC aa (COOH) C26:2 in blood serum; the effective allele is the minor allele

Comment	SNP rs4775041 is located in a linkage disequilibrium block containing the gene coding for LIPC, a key enzyme of the long-chain fatty acid metabolism. This polymorphism associates with the concentrations of numerous glycerophosphatidylcholines, glycerophosphatidylethanolamines and sphingomyelins. Homozygotes carrying the minor allele have on average 70% higher concentrations of the phosphatidylethanolamine diacyl C38:6 (PE aa C38:6) than homozygotes for the major allele. The molecular function of LIPC is to break-down triglycerides to diacyl- and monoacylglycerols and fatty acids, which makes this association functionally plausible. In previous GWA studies this locus was reported to be associated with HDL cholesterol and triglyceride levels.
Formal Description Interaction-ID: 41645	SNP LIPC rs4775041 decreases_quantity of drug/chemical compound Glutamate in blood serum; the effective allele is the minor allele

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41650	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Arg/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41652	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Met/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41653	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Lys/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41655	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Gly/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41656	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Orn/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41657	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating His/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41658	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Trp/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41659	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Thr/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41660	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Phe/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41661	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Met.sulf/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41662	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Tyr/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41663	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Ala/Glu ratio in blood serum

Comment	A polymorphism in the PARK2 gene (rs992037) alters the concentrations of several amino acids. Some of these amino acids are directly connected to the urea cycle. PARK2 codes for parkin, a ubiquitin ligase for which a loss-of-function mutation has been reported to result in Parkinson's disease. When using ratios between metabolite concentrations we observed up to three orders of magnitude smaller p-values. This suggests that this polymorphism impacts some metabolic pathway that involves glutamate on the one hand and a number of other amino acids (except lysine) on the other hand. Thus, the metabolic footprint of this association is that of an amino acid interconversion, which is supported by the functional role of PARK2 as a ubiquitin ligase in the protein degradation pathway.
Formal Description Interaction-ID: 41664	SNP PRKN rs992037 affects_activity of phenotype abnormal circulating Cit/Glu ratio in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41665	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C14:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41736	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C16:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41737	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C42:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41738	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C22:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41739	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM (COOH) C12:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41740	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C18:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41741	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C26:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41742	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa (COOH) C26:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41743	SNP PLEK rs9309413 decreases_quantity of drug/chemical compound SM C24:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41744	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C24:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41745	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa C28:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41746	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa (OH, COOH) C28:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41747	SNP PLEK rs9309413 decreases_quantity of drug/chemical compound PI aa (OH, COOH) C28:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41748	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM (COOH) C18:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41749	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C18:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41750	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C24:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41751	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C38:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41752	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PE aa (COOH) C14:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41753	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PE ae (OH, COOH) C14:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41754	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C40:5 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41755	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C22:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41756	SNP PLEK rs9309413 decreases_quantity of drug/chemical compound SM C20:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41757	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C40:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41758	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C38:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41759	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C20:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41760	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM (OH) C20:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41761	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C36:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41762	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C32:7 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41763	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C20:1 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41764	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PE e C14:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41765	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa (COOH) C30:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41766	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae (OH, COOH) C30:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41767	SNP PLEK rs9309413 increases_quantity of drug/chemical compound Docosahexaenoic acid in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41768	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa C36:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41769	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C26:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41770	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa (OH, COOH) C30:4 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41771	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM (COOH) C16:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41772	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae C32:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41773	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC aa (COOH) C14:2 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41774	SNP PLEK rs9309413 increases_quantity of drug/chemical compound SM C22:0 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41775	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC ae (COOH) C30:3 in blood serum

Comment	SNP rs9309413 lies 21 kb upstream of PLEK. The PLEK gene codes for pleckstrin, a protein that has been proposed to facilitate protein-lipid interactions and to affect membrane structure. SNP rs9309413 impacts on a number of sphingomyelins, which are known to play a major role in membrane lipid structure.
Formal Description Interaction-ID: 41776	SNP PLEK rs9309413 increases_quantity of drug/chemical compound PC a C18:1 in blood serum

Comment	The study identified two new loci: the first polymorphism is located in the gene coding for the short-chain acyl-Coenzyme A dehydrogenase (SCAD; e.g. intronic SNP rs2014355), the second lies in the gene coding for the mediumchain acyl-Coenzyme A dehydrogenase (MCAD; e.g. intronic SNP rs11161510). Both genes code for enzymes that initiate the beta-oxidation of fatty acids, but they differ in the preference for their chain lengths. The metabolite pair that associates most strongly with rs2014355 of SCAD is the ratio between the shortchain acylcarnitines C3 and C4, while the pair that associates most strongly with rs11161510 of MCAD is the ratio between the medium-chain acylcarnitines C12 and C8. Fatty acids are bound to free carnitine for transport and beta-oxidation into the mitochondria. The short-chain acylcarnitines can be considered as indirect substrates and products of SCAD and the medium-chain acylcarnitines as indirect substrates of MCAD, which matches the biochemical function of these enzymes. From the direction of the effect of these polymorphisms (higher concentrations of the longer chain fatty acids (= substrates) when compared to the smaller chain fatty acids (= products) implies a reduced dehydrogenase activity) it can further be deduced that in both cases minor allele homozygotes have the lowest enzymatic turnover for these reactions.
Formal Description Interaction-ID: 41777	SNP ACADS rs2014355 affects_activity of phenotype abnormal circulating acylcarnitine C3/C4 ratio in blood serum

Comment	The study identified two new loci: the first polymorphism is located in the gene coding for the short-chain acyl-Coenzyme A dehydrogenase (SCAD; e.g. intronic SNP rs2014355), the second lies in the gene coding for the mediumchain acyl-Coenzyme A dehydrogenase (MCAD; e.g. intronic SNP rs11161510). Both genes code for enzymes that initiate the beta-oxidation of fatty acids, but they differ in the preference for their chain lengths. The metabolite pair that associates most strongly with rs2014355 of SCAD is the ratio between the shortchain acylcarnitines C3 and C4, while the pair that associates most strongly with rs11161510 of MCAD is the ratio between the medium-chain acylcarnitines C12 and C8. Fatty acids are bound to free carnitine for transport and beta-oxidation into the mitochondria. The short-chain acylcarnitines can be considered as indirect substrates and products of SCAD and the medium-chain acylcarnitines as indirect substrates of MCAD, which matches the biochemical function of these enzymes. From the direction of the effect of these polymorphisms (higher concentrations of the longer chain fatty acids (= substrates) when compared to the smaller chain fatty acids (= products) implies a reduced dehydrogenase activity) it can further be deduced that in both cases minor allele homozygotes have the lowest enzymatic turnover for these reactions.
Formal Description Interaction-ID: 41778	SNP ACADM rs11161510 affects_activity of phenotype abnormal circulating acylcarnitine C12/C8 ratio in blood serum

Comment	The study identified two new loci: the first polymorphism is located in the gene coding for the short-chain acyl-Coenzyme A dehydrogenase (SCAD; e.g. intronic SNP rs2014355), the second lies in the gene coding for the mediumchain acyl-Coenzyme A dehydrogenase (MCAD; e.g. intronic SNP rs11161510). Both genes code for enzymes that initiate the beta-oxidation of fatty acids, but they differ in the preference for their chain lengths. The metabolite pair that associates most strongly with rs2014355 of SCAD is the ratio between the shortchain acylcarnitines C3 and C4, while the pair that associates most strongly with rs11161510 of MCAD is the ratio between the medium-chain acylcarnitines C12 and C8. Fatty acids are bound to free carnitine for transport and beta-oxidation into the mitochondria. The short-chain acylcarnitines can be considered as indirect substrates and products of SCAD and the medium-chain acylcarnitines as indirect substrates of MCAD, which matches the biochemical function of these enzymes. From the direction of the effect of these polymorphisms (higher concentrations of the longer chain fatty acids (= substrates) when compared to the smaller chain fatty acids (= products) implies a reduced dehydrogenase activity) it can further be deduced that in both cases minor allele homozygotes have the lowest enzymatic turnover for these reactions.
Formal Description Interaction-ID: 41779	SNP ACADS rs2014355 decreases_activity of gene/protein ACADS the effective allele is the minor allele
Drugbank entries	Show/Hide entries for ACADS
Drugbank DB00157	NADH not specified ACADS
Drugbank DB03059	Acetoacetyl-Coenzyme A not specified ACADS
Drugbank DB03147	Flavin-Adenine Dinucleotide not specified ACADS
Drugbank DB00157	NADH not specified ACADS
Drugbank DB03059	Acetoacetyl-Coenzyme A not specified ACADS
Drugbank DB03147	Flavin-Adenine Dinucleotide not specified ACADS

Comment	The study identified two new loci: the first polymorphism is located in the gene coding for the short-chain acyl-Coenzyme A dehydrogenase (SCAD; e.g. intronic SNP rs2014355), the second lies in the gene coding for the mediumchain acyl-Coenzyme A dehydrogenase (MCAD; e.g. intronic SNP rs11161510). Both genes code for enzymes that initiate the beta-oxidation of fatty acids, but they differ in the preference for their chain lengths. The metabolite pair that associates most strongly with rs2014355 of SCAD is the ratio between the shortchain acylcarnitines C3 and C4, while the pair that associates most strongly with rs11161510 of MCAD is the ratio between the medium-chain acylcarnitines C12 and C8. Fatty acids are bound to free carnitine for transport and beta-oxidation into the mitochondria. The short-chain acylcarnitines can be considered as indirect substrates and products of SCAD and the medium-chain acylcarnitines as indirect substrates of MCAD, which matches the biochemical function of these enzymes. From the direction of the effect of these polymorphisms (higher concentrations of the longer chain fatty acids (= substrates) when compared to the smaller chain fatty acids (= products) implies a reduced dehydrogenase activity) it can further be deduced that in both cases minor allele homozygotes have the lowest enzymatic turnover for these reactions.
Formal Description Interaction-ID: 41780	SNP ACADM rs11161510 decreases_activity of gene/protein ACADM the effective allele is the minor allele
Drugbank entries	Show/Hide entries for ACADM
Drugbank DB02910	Octanoyl-Coenzyme A not specified ACADM
Drugbank DB03147	Flavin-Adenine Dinucleotide not specified ACADM
Drugbank DB03415	3-Thiaoctanoyl-Coenzyme A not specified ACADM
Drugbank DB02910	Octanoyl-Coenzyme A not specified ACADM
Drugbank DB03147	Flavin-Adenine Dinucleotide not specified ACADM
Drugbank DB03415	3-Thiaoctanoyl-Coenzyme A not specified ACADM

Home
Contact

The Helmholtz Zentrum München Imprint and Privacy Policy apply.

© 2013 - Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH) Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany

Disclaimer: IBIS Databases and associated information are protected by copyright. This server and its associated data and services are for academic, non-commercial use only. The Helmholtz Zentrum München has no liability for the use of results, data or information which have been provided through this server. Neither the use for commercial purposes, nor the redistribution of IBIS database files to third parties nor the distribution of parts of files or derivative products to any third parties is permitted. Commercial users shall contact the Helmholtz Zentrum München for a separate users license.